experts

Dr. Luca Mignani obtained his PhD in molecular genetics, biotechnology and experimental medicine at the University of Brescia (Italy) in 2022. During his PhD program, his research activity focused mainly on the use of zebrafish for the study of neurodegenerative diseases and cancer. In the last two years, he continued his research activity at the University of Brescia to study the role of PTX3 in medulloblastoma and glioblastoma and to investigate the impact of the sphingolipid metabolizing enzyme beta-galactosyl ceramidase in melanoma progression.